Abstract
Effects on 5-HT function of sibutramine and its active metabolites, BTS 54 354 and BTS 54 505, were compared with fluoxetine, (+)-fenfluramine and (+)-amphetamine.
In vitro sibutramine weakly inhibited [3H]-5-HT uptake into brain synaptosomes. BTS 54 354, BTS 54 505 and fluoxetine were powerful [3H]-5-HT uptake inhibitors, whereas (+)-fenfluramine and (+)-amphetamine were very much weaker. Conversely, whilst sibutramine, its metabolites and fluoxetine did not release [3H]-5-HT from brain slices at ⩽10−5M, (+)-fenfluramine and (+)-amphetamine concentration-dependently increased [3H]-5-HT release.
Sibutramine and fluoxetine had no effect on 5-hydroxytryptophan (5-HTP) accumulation in either frontal cortex or hypothalamus at doses <10 mg kg−1. In contrast, (+)-amphetamine (⩾3 mg kg−1) reduced 5-HTP in hypothalamus, whilst (+)-fenfluramine (⩾1 mg kg−1) decreased 5-HTP in both regions.
Sibutramine (10 mg kg−1 i.p.) and fluoxetine (10 mg kg−1 i.p.) produced slow, prolonged increases of extracellular 5-HT in the anterior hypothalamus. In contrast, (+)-fenfluramine (3 mg kg−1 i.p.) and (+)-amphetamine (4 mg kg−1 i.p.) induced rapid, short-lasting increases in extracellular 5-HT.
Only (+)-fenfluramine (10 mg kg−1) altered 5-HT2A receptors in rat frontal cortex when given for 14 days, producing a 61% reduction in receptor number and a 18% decrease in radioligand affinity.
These results show that sibutramine powerfully enhances central 5-HT function via its secondary and primary amine metabolites; this effect, like that of fluoxetine, is almost certainly mediated through 5-HT uptake inhibition. By contrast, (+)-fenfluramine enhances 5-HT function predominantly by increasing 5-HT release. (+)-Amphetamine, though weaker than (+)-fenfluramine, also enhances 5-HT function by release.
Keywords: Sibutramine, BTS 54 354, BTS 54 505, fluoxetine, (+)-fenfluramine, (+)-amphetamine, central 5-HT function, 5-HT uptake, 5-HT release
Full Text
The Full Text of this article is available as a PDF (337.5 KB).